| scholarly article | Q13442814 |
| P50 | author | Stephen Holt | Q42597657 |
| P2093 | author name string | Edward R Smith | |
| Lawrence P McMahon | |||
| Michael M Cai | |||
| P2860 | cites work | Generation and application of data on biological variation in clinical chemistry | Q31038916 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3357-3365 | |
| P577 | publication date | 2012-06-11 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Biological variability of plasma intact and C-terminal FGF23 measurements | |
| P478 | volume | 97 |
| Q47704837 | 24-hour profile of serum sclerostin and its association with bone biomarkers in men. |
| Q35949312 | 25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population |
| Q50785234 | Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. |
| Q63977287 | Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients |
| Q92157066 | Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study |
| Q90378058 | Bone involvement and mineral metabolism in Williams' syndrome |
| Q44410836 | C-terminal FGF23 fragments: present but not seen? |
| Q47103592 | Calcification Propensity of Serum is Independent of Excretory Renal Function. |
| Q55256623 | Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. |
| Q35067500 | Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease |
| Q44410394 | Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. |
| Q36614486 | Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients |
| Q46248791 | Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice |
| Q90209853 | Effects of erythropoietin on fibroblast growth factor 23 in mice and humans |
| Q36194460 | Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial |
| Q98466926 | European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum biointact parathyroid hormone based on weekly samplings from 91 healthy participants |
| Q48316515 | Evaluation of a New Fully Automated Assay for Plasma Intact FGF23. |
| Q35949319 | FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis |
| Q88523645 | FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study |
| Q54960612 | FGF23 Actions on Target Tissues-With and Without Klotho. |
| Q90624325 | FGF23 and Associated Disorders of Phosphate Wasting |
| Q46192114 | FGF23 and Left Ventricular Hypertrophy in Children with CKD. |
| Q90101217 | FGF23 at the crossroads of phosphate, iron economy and erythropoiesis |
| Q33793927 | FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts |
| Q38636252 | Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study |
| Q61312634 | Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis |
| Q26829294 | Fibroblast growth factor 23 |
| Q35690579 | Fibroblast growth factor 23 and acute kidney injury |
| Q89989500 | Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study |
| Q40279706 | Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis |
| Q34280125 | Fibroblast growth factor 23 in acute kidney injury |
| Q37071263 | Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study |
| Q90043642 | Fibroblast growth factor 23: are we ready to use it in clinical practice? |
| Q40115641 | Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy |
| Q35077013 | High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats |
| Q38970634 | How the reference values for serum parathyroid hormone concentration are (or should be) established? |
| Q38045788 | Hypophosphatemic rickets: unraveling the role of FGF23. |
| Q99576156 | Intact & C-terminal FGF-23 Assays- Do Kidney Function, Inflammation, & Iron Status Influence Relationships with Outcomes? |
| Q55442487 | Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. |
| Q89535456 | Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial |
| Q90678222 | Low doses of recombinant human erythropoietin does not affect C-terminal FGF23 in healthy men |
| Q64257805 | Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients |
| Q36142210 | Nocturnal eating disturbs phosphorus excretion in young subjects: a randomized crossover trial |
| Q57796697 | Non-renal-Related Mechanisms of FGF23 Pathophysiology |
| Q38970563 | Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles. |
| Q28083419 | Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep |
| Q35182281 | Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients |
| Q92356433 | Osteokines and the vasculature: a review of the in vitro effects of osteocalcin, fibroblast growth factor-23 and lipocalin-2 |
| Q51325271 | Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. |
| Q30316351 | Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study |
| Q39056902 | Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis |
| Q36514947 | Renal Clearance of Mineral Metabolism Biomarkers |
| Q34787817 | Serum fibroblast growth factor-23 is associated with incident kidney disease |
| Q89479278 | Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos |
| Q38901793 | Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type |
| Q39049485 | Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner |
| Q64118923 | The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research |
| Q38571195 | The PTH-Vitamin D-FGF23 axis |
| Q51765638 | The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study. |
| Q47578293 | The importance of the circadian system & sleep for bone health. |
| Q38793054 | The role of phosphate in kidney disease |
| Q59340546 | The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort |
| Q33835743 | The use of fibroblast growth factor 23 testing in patients with kidney disease |
| Q36976545 | Toward improved phosphorus efficiency in monogastrics-interplay of serum, minerals, bone, and immune system after divergent dietary phosphorus supply in swine |
| Q38261146 | Tumor-associated FGF-23-induced hypophosphatemic rickets in children: a case report and review of the literature |
| Q48263079 | Vitamin D and renal outcome: the fourth outcome of CKD-MBD? Oshima Award Address 2015. |
Search more.